Albemarle is increasing its prices for the active pharmaceutical ingredient (API) ibuprofen by 15 per cent.
The increase will occur immediately, or as soon as contracts allow, and will raise ibuprofen prices by an estimated 15 per cent. An Albemarle release detailing the price hike lacks information justifying the increase but market dynamics underpinning rises have been widely discussed in recent months.
Many of the leading suppliers of excipients and APIs have spoken of the need to pass on rising raw material costs to customers. Albemarle upped the prices of its generic APIs by around 10 per cent last September, while BASF, ISP, FMC, and others have all enacted ingredient increases too.